12-Jan-2026
No headlines found.
Definitive Healthcare to Present at the 28th Annual Needham Growth Conference
Globe Newswire (Wed, 7-Jan 4:05 PM ET)
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025
Globe Newswire (Thu, 6-Nov 4:05 PM ET)
Globe Newswire (Thu, 23-Oct 4:05 PM ET)
Forum Ventures Bets Big on Category-Defining Vertical AI Solution for Healthcare Growth, Salubrum
Globe Newswire (Fri, 17-Oct 7:00 PM ET)
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Definitive Healthcare Corp. - Class A trades on the NASDAQ stock market under the symbol DH.
As of January 12, 2026, DH stock price declined to $2.54 with 243,290 million shares trading.
DH has a beta of 1.60, meaning it tends to be more sensitive to market movements. DH has a correlation of 0.13 to the broad based SPY ETF.
DH has a market cap of $262.39 million. This is considered a Small Cap stock.
Last quarter Definitive Healthcare Corp. - Class A reported $60 million in Revenue and $.07 earnings per share. This beat revenue expectation by $568,558 and exceeded earnings estimates by $.03.
In the last 3 years, DH traded as high as $14.03 and as low as $2.15.
The top ETF exchange traded funds that DH belongs to (by Net Assets): VTI, IWM, FDLS, VXF, SMLF.
DH has underperformed the market in the last year with a price return of -40.0% while the SPY ETF gained +19.2%. DH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.5% and -3.4%, respectively, while the SPY returned +3.9% and +0.7%, respectively.
DH support price is $2.44 and resistance is $2.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DH shares will trade within this expected range on the day.